These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 15643298)

  • 1. Clinical and biochemical characteristics and genotype-phenotype correlation in 143 Finnish and Russian patients with acute intermittent porphyria.
    Fraunberg MVUZ; Pischik E; Udd L; Kauppinen R
    Medicine (Baltimore); 2005 Jan; 84(1):35-47. PubMed ID: 15643298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute intermittent porphyria: expression of mutant and wild-type porphobilinogen deaminase in COS-1 cells.
    Mustajoki S; Laine M; Lahtela M; Mustajoki P; Peltonen L; Kauppinen R
    Mol Med; 2000 Aug; 6(8):670-9. PubMed ID: 11055586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular and biochemical studies of acute intermittent porphyria in 196 patients and their families.
    Kauppinen R; von und zu Fraunberg M
    Clin Chem; 2002 Nov; 48(11):1891-900. PubMed ID: 12406973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Porphobilinogen deaminase over-expression in hepatocytes, but not in erythrocytes, prevents accumulation of toxic porphyrin precursors in a mouse model of acute intermittent porphyria.
    Unzu C; Sampedro A; Mauleón I; Vanrell L; Dubrot J; de Salamanca RE; González-Aseguinolaza G; Melero I; Prieto J; Fontanellas A
    J Hepatol; 2010 Mar; 52(3):417-24. PubMed ID: 19815305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic and biochemical characterization of 16 acute intermittent porphyria cases with a high prevalence of the R173W mutation.
    To-Figueras J; Badenas C; Carrera C; Muñoz C; Milá M; Lecha M; Herrero C
    J Inherit Metab Dis; 2006 Aug; 29(4):580-5. PubMed ID: 16817012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation and evaluation of two porphobilinogen deaminase activity assays for diagnosis of acute intermittent porphyria.
    Lin CN; Huang YC; Ro LS; Liao MF; Ning HC; Kuo HC
    Clin Chim Acta; 2018 Apr; 479():1-6. PubMed ID: 29317194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of age and gender on the clinical expression of acute intermittent porphyria based on molecular study of porphobilinogen deaminase gene among Swiss patients.
    Schuurmans MM; Schneider-Yin X; Rüfenacht UB; Schnyder C; Minder CE; Puy H; Deybach JC; Minder EI
    Mol Med; 2001 Aug; 7(8):535-42. PubMed ID: 11591889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The W198X and R173W mutations in the porphobilinogen deaminase gene in acute intermittent porphyria have higher clinical penetrance than R167W. A population-based study.
    Andersson C; Floderus Y; Wikberg A; Lithner F
    Scand J Clin Lab Invest; 2000 Nov; 60(7):643-8. PubMed ID: 11202057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Porphobilinogen deaminase gene mutations in Polish patients with non-erythroid acute intermittent porphyria.
    Szlendak U; Lipniacka A; Bianketti J; Podolak-Dawidziak M; Bykowska K
    Adv Clin Exp Med; 2015; 24(1):63-8. PubMed ID: 25923088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical characterization of porphobilinogen deaminase-deficient mice during phenobarbital induction of heme synthesis and the effect of enzyme replacement.
    Johansson A; Möller C; Fogh J; Harper P
    Mol Med; 2003; 9(9-12):193-9. PubMed ID: 15208740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homozygous hydroxymethylbilane synthase knock-in mice provide pathogenic insights into the severe neurological impairments present in human homozygous dominant acute intermittent porphyria.
    Yasuda M; Gan L; Chen B; Yu C; Zhang J; Gama-Sosa MA; Pollak DD; Berger S; Phillips JD; Edelmann W; Desnick RJ
    Hum Mol Genet; 2019 Jun; 28(11):1755-1767. PubMed ID: 30615115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal failure affects the enzymatic activities of the three first steps in hepatic heme biosynthesis in the acute intermittent porphyria mouse.
    Unzu C; Sampedro A; Sardh E; Mauleón I; Enríquez de Salamanca R; Prieto J; Salido E; Harper P; Fontanellas A
    PLoS One; 2012; 7(3):e32978. PubMed ID: 22412963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feline acute intermittent porphyria: a phenocopy masquerading as an erythropoietic porphyria due to dominant and recessive hydroxymethylbilane synthase mutations.
    Clavero S; Bishop DF; Haskins ME; Giger U; Kauppinen R; Desnick RJ
    Hum Mol Genet; 2010 Feb; 19(4):584-96. PubMed ID: 19934113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular study of the hydroxymethylbilane synthase gene (HMBS) among Polish patients with acute intermittent porphyria.
    Gregor A; Schneider-Yin X; Szlendak U; Wettstein A; Lipniacka A; Rüfenacht UB; Minder EI
    Hum Mutat; 2002 Mar; 19(3):310. PubMed ID: 11857754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Steady-state transcript levels of the porphobilinogen deaminase gene in patients with acute intermittent porphyria.
    Mustajoki S; Kauppinen R; Mustajoki P; Suomalainen A; Peltonen L
    Genome Res; 1997 Nov; 7(11):1054-60. PubMed ID: 9371741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haem precursors and porphobilinogen deaminase in erythrocytes and lymphocytes of patients with acute intermittent porphyria.
    Gross U; Jacob K; Frank M; Doss MO
    Cell Mol Biol (Noisy-le-grand); 1997 Feb; 43(1):29-35. PubMed ID: 9074786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and expression of mutations in the hydroxymethylbilane synthase gene causing acute intermittent porphyria (AIP).
    Solis C; Lopez-Echaniz I; Sefarty-Graneda D; Astrin KH; Desnick RJ
    Mol Med; 1999 Oct; 5(10):664-71. PubMed ID: 10602775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of volatile anaesthetics on heme metabolism in a murine genetic model of Acute Intermittent Porphyria. A comparative study with other porphyrinogenic drugs.
    Ruspini SF; Zuccoli JR; Lavandera JV; Martínez MDC; Oliveri LM; Gerez EN; Batlle AMDC; Buzaleh AM
    Biochim Biophys Acta Gen Subj; 2018 Jun; 1862(6):1296-1305. PubMed ID: 29476795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute intermittent porphyria: prevalence of mutations in the porphobilinogen deaminase gene in blood donors in France.
    Nordmann Y; Puy H; Da Silva V; Simonin S; Robreau AM; Bonaiti C; Phung LN; Deybach JC
    J Intern Med; 1997 Sep; 242(3):213-7. PubMed ID: 9350165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High penetrance of acute intermittent porphyria in a Spanish founder mutation population and CYP2D6 genotype as a susceptibility factor.
    Barreda-Sánchez M; Buendía-Martínez J; Glover-López G; Carazo-Díaz C; Ballesta-Martínez MJ; López-González V; Sánchez-Soler MJ; Rodriguez-Peña L; Serrano-Antón AT; Gil-Ferrer R; Martínez-Romero MDC; Carbonell-Meseguer P; Guillén-Navarro E
    Orphanet J Rare Dis; 2019 Feb; 14(1):59. PubMed ID: 30808393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.